| 25.965 -0.315 (-1.2%) | 06-20 11:34 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 33.16 |
1-year : | 35.2 |
| Resists | First : | 28.39 |
Second : | 30.13 |
| Pivot price | 27.13 |
|||
| Supports | First : | 25.55 |
Second : | 21.26 |
| MAs | MA(5) : | 26.28 |
MA(20) : | 27.21 |
| MA(100) : | 27.77 |
MA(250) : | 44.3 |
|
| MACD | MACD : | -0.2 |
Signal : | 0 |
| %K %D | K(14,3) : | 11.9 |
D(3) : | 17.4 |
| RSI | RSI(14): 42.6 |
|||
| 52-week | High : | 81.73 | Low : | 18.92 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ VKTX ] has closed above bottom band by 14.9%. Bollinger Bands are 32.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 26.9 - 27.05 | 27.05 - 27.22 |
| Low: | 25.38 - 25.55 | 25.55 - 25.73 |
| Close: | 25.96 - 26.26 | 26.26 - 26.57 |
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Mon, 16 Jun 2025
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet - Yahoo Finance
Mon, 16 Jun 2025
Viking Therapeutics Stock (VKTX): This Underrated Russell 2000 Gem Could Skyrocket 200% - TipRanks
Thu, 12 Jun 2025
Viking Therapeutics (VKTX) Rises on Expected Developments - MSN
Thu, 12 Jun 2025
Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
Tue, 03 Jun 2025
Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Fri, 30 May 2025
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 112 (M) |
| Shares Float | 110 (M) |
| Held by Insiders | 2.1 (%) |
| Held by Institutions | 70 (%) |
| Shares Short | 25,540 (K) |
| Shares Short P.Month | 25,460 (K) |
| EPS | -1.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.53 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -11.8 % |
| Return on Equity (ttm) | -14.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -134 (M) |
| Levered Free Cash Flow | -98 (M) |
| PE Ratio | -22.15 |
| PEG Ratio | 0 |
| Price to Book value | 3.4 |
| Price to Sales | 0 |
| Price to Cash Flow | -21.54 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|